Premium
Synergistic Inhibition of Tumor Cell Proliferation by Cold Plasma and Gemcitabine
Author(s) -
Masur Kai,
von Behr Magdalena,
Bekeschus Sander,
Weltmann KlausDieter,
Hackbarth Christine,
Heidecke ClausDieter,
von Bernstorff Wolfram,
von Woedtke Thomas,
Partecke Lars Ivo
Publication year - 2015
Publication title -
plasma processes and polymers
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.644
H-Index - 74
eISSN - 1612-8869
pISSN - 1612-8850
DOI - 10.1002/ppap.201500123
Subject(s) - gemcitabine , apoptosis , plasma medicine , in vitro , chemistry , atmospheric pressure plasma , fibroblast , cytotoxicity , cancer research , cell growth , pharmacology , cancer , biology , plasma , biochemistry , medicine , physics , quantum mechanics
In the field of plasma medicine, cold atmospheric pressure plasma (CAP) is applied to biological matter for a therapeutic benefit. The latter is mediated by CAP‐generated reactive species which treatment time‐dependently either stimulate cells or induce their apoptosis. Accordingly, antitumor effects of plasma have been observed previously, but only few studies have included proper controls to compare the plasma's cytotoxicity. We here present results that murine cancer cells are more susceptible to CAP treatment compared to non‐malignant fibroblasts in vitro. Additional challenge with the chemotherapeutic Gemcitabine significantly enhanced tumor cell but not fibroblast metabolic inhibition, suggesting potential combinatory effects in anticancer therapy.